Advanced Search

Study Preview



Study Title and Description

Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Fecal secretory immunoglobulin A is increased in healthy infants who receive a formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides.
Author Scholtens PA., Alliet P., Raes M., Alles MS., Kroes H., Boehm G., Knippels LM., Knol J., Vandenplas Y.
Country Numico Research, Wageningen 6700 CA, The Netherlands. petra.scholtens@numico-research.nl
Year 2008
Numbers Pubmed ID: 18492847

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2008
  • Comments Comments (
    0
    ) |
country Belgium
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
feedcontrol All food provided (metabolic study)
  • Comments Comments (
    0
    ) |
sampsize 215
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Not applicable
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant 1
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 0
  • Comments Comments (
    0
    ) |
age_range 0-6 months
  • Comments Comments (
    0
    ) |
bmi_mean NR
  • Comments Comments (
    0
    ) |
bmi_range
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~55
  • Comments Comments (
    0
    ) |
ftype1 Combination/Mixture
  • Comments Comments (
    0
    ) |
descrip1_1 GOS
  • Comments Comments (
    0
    ) |
descrip1_2 lcFOS
  • Comments Comments (
    0
    ) |
dose1_1 5.4 g/L
  • Comments Comments (
    0
    ) |
dose1_2 0.6 g/L
  • Comments Comments (
    0
    ) |
duration1 26 weeks
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 control
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 26 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Powder
  • Comments Comments (
    0
    ) |
comparator2 breastmilk
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2 26 weeks
  • Comments Comments (
    0
    ) |
cadmin2 Diet
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.